The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy
Fig 2
CBP-93872 enhances oxaliplatin-, cisplatin- and gemcitabine-induced apoptosis in HT29 cells or Panc-1 cells.
(A, B) HT29 cells were treated with oxaliplatin (30 μM) (A) or cisplatin (30 μM) (B) in the presence or absence of CBP-93872 (50 μM). Cells were harvested at 72 hrs, fixed and subjected to FACS analysis (left panels). The percentages of cells in sub-G1 phase are shown in the panels on the right. Data are presented as means ± SD (n = 3). Statistical significance was calculated using Student’s t-test (*, p < 0.01). (C) Panc-1 cells were treated with gemcitabine (0.1 μM) in the presence or absence of CBP-93872 (200 μM). (D-F) HT29 cells or Panc-1 cells, were collected at the times indicated. Total cell extracts were subjected to immunoblotting, using the indicated antibodies.